Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The study compared the efficacy and assessed the safety of secukinumab given as 3 intravenous
(i.v.) loading doses or weekly sub-cutaneous (s.c.) loading doses, compared to placebo,
followed by monthly s.c. injections in patients with active Rheumatoid Arthritis (RA) despite
treatment with Methotrexate.